Bristol-Myers Squibb Company PFD CONV 2

(PINK:BMYMP)

Latest On Bristol-Myers Squibb Company PFD CONV 2 (BMYMP):

Date/Time Type Description Signal Details
2024-01-29 04:57 ESTDividendA dividend of $0.5 has been announced on Dec 6, 2023. It will be paid Mar 1, 2024 with an ex-dividend date of Jan 29, 2024.Neutral
2023-10-30 05:56 ESTDividendA dividend of $0.5 has been announced on Sep 20, 2023. It will be paid Dec 1, 2023 with an ex-dividend date of Oct 30, 2023.Neutral
2023-07-31 05:56 ESTDividendA dividend of $0.5 has been announced on Jun 14, 2023. It will be paid Sep 1, 2023 with an ex-dividend date of Jul 31, 2023.Neutral
2023-05-13 22:34 ESTNewsBristol-Myers Squibb Company (BMY) Presents at Bank of America Securities 2023 Health Care Conference (Transcript)N/A
2023-05-01 05:55 ESTDividendA dividend of $0.5 has been announced on Mar 3, 2023. It will be paid Jun 1, 2023 with an ex-dividend date of May 1, 2023.Neutral
2023-04-27 12:03 ESTNewsBristol-Myers Squibb Company (BMY) Q1 2023 Earnings Call TranscriptN/A
2023-04-27 12:03 ESTNewsBristol-Myers Squibb Company 2023 Q1 - Results - Earnings Call PresentationN/A
2023-03-08 02:40 ESTNewsBristol-Myers Squibb Company (BMY) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)N/A
2023-02-20 15:29 ESTNewsWhat To Expect From Bristol-Myers Squibb In 2023N/A
2023-02-03 01:25 ESTNewsBristol-Myers Squibb Company (BMY) Q4 2022 Earnings Call TranscriptN/A
2023-01-30 04:56 ESTDividendA dividend of $0.5 has been announced on Dec 8, 2022. It will be paid Mar 1, 2023 with an ex-dividend date of Jan 30, 2023.Neutral
2023-01-18 12:57 ESTNewsWhy Bristol Myers Squibb Is The Better Buy From U.S. Large Cap PharmaN/A
2023-01-09 22:13 ESTNewsBristol-Myers Squibb Co. (BMY) J.P. Morgan 41st Annual Healthcare Conference (Transcript)N/A
2022-11-16 20:21 ESTNewsBristol-Myers Squibb Company (BMY) Presents at 4th Annual Wolfe Research Healthcare Conference (Transcript)N/A
2022-11-07 04:56 ESTDividendA dividend of $0.5 has been announced on Sep 14, 2022. It will be paid Dec 1, 2022 with an ex-dividend date of Nov 7, 2022.Neutral
2022-10-27 01:04 ESTNewsBristol-Myers Squibb Co (BMY) Q3 2022 Earnings Call TranscriptN/A
2022-09-13 02:21 ESTNewsBristol-Myers Squibb Co (BMY) Morgan Stanley Global Healthcare Conference Call TranscriptN/A
2022-09-09 13:28 ESTNewsBristol-Myers Squibb (BMY) Investor Presentations - SlideshowN/A
2022-09-08 20:01 ESTNewsBristol-Myers Squibb Company (BMY) Presents at Citi's 17th Annual BioPharma Conference (Transcript)N/A
2022-08-08 05:55 ESTDividendA dividend of $0.5 has been announced on Jun 15, 2022. It will be paid Sep 1, 2022 with an ex-dividend date of Aug 8, 2022.Neutral
2022-07-29 06:25 ESTNewsBristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio on Q2 2022 Results - Earnings Call TranscriptN/A
2022-07-27 11:45 ESTNewsBristol-Myers Squibb Company 2022 Q2 - Results - Earnings Call PresentationN/A
2022-07-27 11:45 ESTNewsBristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q2 2022 Results - Earnings Call TranscriptN/A
2022-06-30 01:59 ESTNewsBristol-Myers Squibb: When Will The Correction End?N/A
2022-06-15 17:40 ESTNewsBristol-Myers Squibb Company (BMY) Management presents at Goldman Sachs 43rd Annual Global Healthcare ConferenceN/A
2022-06-04 10:08 ESTNewsBristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at Bernstein 38th Annual Strategic Decisions Conference (Transcript)N/A
2022-06-02 17:14 ESTNewsBristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Bernstein 38th Annual Strategic Decisions Conference (Transcript)N/A
2022-05-09 05:55 ESTDividendA dividend of $0.5 has been announced on Mar 1, 2022. It will be paid Jun 1, 2022 with an ex-dividend date of May 9, 2022.Neutral
2022-04-29 15:20 ESTNewsBristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q1 2022 Results - Earnings Call TranscriptN/A
2022-04-29 15:20 ESTNewsBristol-Myers Squibb Company 2022 Q1 - Results - Earnings Call PresentationN/A
2022-03-18 03:45 ESTNewsBristol-Myers Squibb Co (BMY) Presents at Barclays Global Healthcare Broker Conference Call - (Transcript)N/A
2022-02-08 08:36 ESTNewsBristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-05 05:30 ESTNewsBristol-Myers Squibb Co (BMY) CEO Giovanni Caforio on Q4 2021 Results - Earnings Call TranscriptN/A
2022-01-31 04:56 ESTDividendA dividend of $0.5 has been announced on Dec 13, 2021. It will be paid Mar 1, 2022 with an ex-dividend date of Jan 31, 2022.Neutral
2022-01-13 07:00 ESTNewsBristol-Myers Squibb (BMY) Presents At 40th Annual J.P. Morgan Healthcare ConferenceN/A
2022-01-11 20:36 ESTNewsBristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at JPMorgan 40th Annual Healthcare Brokers Conference (Transcript)N/A
2022-01-11 03:59 ESTNewsBristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at JPMorgan 40th Annual Healthcare Brokers Conference (Transcript)N/A
2021-11-19 23:02 ESTNewsBristol-Myers Squibb (BMY) Investor Presentation - SlideshowN/A
2021-11-08 04:56 ESTDividendA dividend of $0.5 has been announced on Sep 9, 2021. It will be paid Dec 1, 2021 with an ex-dividend date of Nov 8, 2021.Neutral
2021-10-29 09:01 ESTNewsBristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-28 06:08 ESTNewsBristol Myers Squibb (BMY) CEO Giovanni Caforio on Q3 2021 Results - Earnings Call TranscriptN/A
2021-10-28 06:07 ESTNewsBristol-Myers Squibb Company 2021 Q3 - Results - Earnings Call PresentationN/A
2021-09-22 12:02 ESTNewsBristol-Myers Squibb Company's (BMY) CEO Giovanni Caforio Presents at Morgan Stanley 19th Annual Global Healthcare Brokers Conference (Transcript)N/A
2021-08-31 18:01 ESTNewsBristol Myers Squibb: Why Wall Street Is Wrong About The StockN/A
2021-08-09 05:57 ESTDividendA dividend of $0.5 has been announced on Jun 17, 2021. It will be paid Sep 1, 2021 with an ex-dividend date of Aug 9, 2021.Neutral
2021-07-30 04:41 ESTNewsBristol-Myers Squibb Company 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-29 07:48 ESTNewsBristol Myers Squibb (BMY) CEO Giovanni Caforio on Q2 2021 Results - Earnings Call TranscriptN/A
2021-07-22 10:33 ESTNewsBristol-Myers Squibb Company (BMY) Management Presents at UBS Global Healthcare 2021 Virtual Conference (Transcript)N/A
2021-07-22 10:30 ESTNewsBristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Bernstein's 37th Annual Strategic Decisions Conference (Transcript)N/A
2021-07-22 10:28 ESTNewsBristol-Myers Squibb Company's (BMY) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)N/A

About Bristol-Myers Squibb Company PFD CONV 2 (BMYMP):

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

See Advanced Chart

General

  • Name Bristol-Myers Squibb Company PFD CONV 2
  • Symbol BMYMP
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorOther
  • IndustryOther
  • Full Time Employees 23,700
  • Fiscal Year EndDecember
View More

Valuation

  • Trailing PE 4755.56
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.75 trillion
  • PE Ratio 12.34
View More

Share Statistics

  • % Held by Insiders <1%
View More

Technicals

  • 52 Week High $1497.19
  • 52 Week Low $779.44
  • 50 Day Moving Average 1116.25
  • 200 Day Moving Average 1115.1
View More

Dividends

  • Forward Annual Dividend Yield 0.12%
  • Dividend Date 2021-06-01
  • ExDividend Date N/A
  • Dividend Per Share $1.59
  • Dividend Yield 0%
View More

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Dividend Calendar:

BMYMP's last dividend payment was made to shareholders on June 1, 2021.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-12-31$10.54 billion-$4.45$0.00
2020-06-302020-09-30$10.13 billion$0.82$0.00
2020-03-312020-06-30$10.78 billion-$0.04$0.00
2019-12-312020-03-31$7.95 billion-$0.34$0.00
2019-09-302019-12-31$6.01 billion-$0.55$0.00
2019-06-302019-09-30$6.27 billion$0.83$0.00
2019-03-312019-06-30$5.92 billion$0.87$0.00
2018-12-312019-03-31$1.04$0.00
2018-09-302018-12-31$0.71$0.00
2018-06-302018-09-30$1.16$0.00
2018-03-312018-06-30$5.19 billion$0.23$0.00
2017-12-312018-03-31$5.45 billion$0.91$0.00
2017-09-302017-12-31$5.25 billion-$1.43$0.00
2017-06-302017-09-30$5.14 billion$0.51$0.00
2017-03-312017-06-30$4.93 billion$0.56$0.00
2016-12-312017-03-31$0.94$0.00
2016-09-302016-12-31$0.53$0.00
2016-06-302016-09-30$0.72$0.00
2016-03-312016-06-30$0.69$0.00
2015-12-312016-03-31$0.71$0.00
2015-09-302015-12-31-$0.12$0.00
2015-06-302015-09-30$0.42$0.00
2015-03-312015-06-30-$0.08$0.00
2014-12-312015-03-31$0.71$0.00
2014-09-302014-12-31$0.01$0.00
2014-06-302014-09-30$0.43$0.00
2014-03-312014-06-30$0.20$0.00
2013-12-312014-03-31$0.56$0.00
2013-09-302013-12-31$0.43$0.00
2013-06-302013-09-30$0.42$0.00
2013-03-312013-06-30$0.32$0.00
2012-12-312013-03-31$0.37$0.00
2012-09-302012-12-31$0.56$0.00
2012-06-302012-09-30-$0.43$0.00
2012-03-312012-06-30$0.38$0.00
2011-12-312012-03-31$0.64$0.00
2011-09-302011-12-31$0.50$0.00
2011-06-302011-09-30$0.56$0.00
2011-03-312011-06-30$0.52$0.00
2010-12-312011-03-31$0.57$0.00

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 3.75 billion 2.5 billion 2.52 billion 2.37 billion 2.09 billion
Income Before Tax -10.45 billion 2.26 billion 1.63 billion -304 million -129 million
Selling General Administrative 2.72 billion 1.71 billion 1.63 billion 1.61 billion 1.73 billion
Gross Profit 8.16 billion 8.04 billion 7.43 billion 7.12 billion 5.51 billion
Ebit -7.57 billion 5.26 billion 4.54 billion 2.54 billion 1.39 billion
Operating Income -839 million 1.34 billion 891 million 783 million 557 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue 11.07 billion 10.54 billion 10.13 billion 10.78 billion 7.95 billion
Cost of Revenue 2.91 billion 2.5 billion 2.7 billion 3.66 billion 2.43 billion
Total Other Income Expense Net -9.26 billion 1.26 billion 1.09 billion -725 million -407 million
Net Income From Continuing Operations -10.03 billion 1.88 billion -80 million -766 million -1.06 billion
Net Income Applicable to Common Shares N/A N/A N/A N/A N/A
Cash Flow:
Date Mar 31 2020 Dec 31 2019 Sep 30 2019 Jun 30 2019 Mar 31 2019
Investments 653 million -12.04 billion 491 million 715 million 1.06 billion
Change to Liabilities N/A N/A N/A N/A N/A
Total Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities -1.05 billion -7.68 billion -941 million 18.27 billion -2.03 billion
Change to Operating Activities N/A N/A N/A N/A N/A
Change in Cash 3.43 billion -17.67 billion 2.09 billion 21.07 billion 424 million
Total Cash from Operating Activities 3.89 billion N/A N/A N/A N/A
Depreciation 2.48 billion 1.24 billion 171 million 169 million 170 million
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory 1.45 billion 470 million -35 million -7 million 35 million
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income N/A N/A N/A N/A N/A
Capital Expenditures 186 million 251 million 190 million 191 million 204 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A 75.31 billion 78.92 billion 79.31 billion 78.25 billion
Total Stockholder Equity N/A 50.16 billion 49.09 billion 49.91 billion 51.6 billion
Other Current Liabilities N/A 11.12 billion 11 billion 8.06 billion 7.89 billion
Total Assets N/A 125.54 billion 128.08 billion 129.29 billion 129.94 billion
Common Stock N/A N/A N/A N/A N/A
Other Current Assets N/A 1.35 billion 1.38 billion 2.41 billion 1.98 billion
Retained Earnings N/A 32.41 billion 31.57 billion 32.67 billion 34.47 billion
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A N/A N/A N/A
Cash 14.55 billion 19.44 billion 19.93 billion 15.82 billion 12.35 billion
Total Current Liabilities N/A 20.46 billion 23.42 billion 19.23 billion 18.3 billion
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment N/A N/A N/A N/A N/A
Total Current Assets N/A 34.28 billion 34.34 billion 31.85 billion 29.35 billion
Long Term Investments N/A 4.66 billion 4.41 billion 651 million 767 million
Net Tangible Assets N/A N/A N/A N/A N/A
Short Term Investments 1.29 billion 1.85 billion 1.86 billion 2.51 billion 3.05 billion
Long Term Debt N/A 41.36 billion 41.85 billion 42.84 billion 43.39 billion
Inventory N/A 1.95 billion 2.38 billion 2.84 billion 4.29 billion
Accounts Payable N/A 2.44 billion 2.85 billion 3.07 billion 2.45 billion

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Chart:

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) News:

Below you will find a list of latest news for Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link